FermenGIN Receives FDA NDI Notification
The bioconverted Korean red ginseng extract has officially cleared federal safety notification requirements.
Updated on Oct. 15, 2026 in Nutrition
Live Poll
Do you trust that bio-engineered supplement processing significantly improves the health benefits you receive?
The U.S. Food and Drug Administration has issued NDI Notification number 1362 to FermenGIN, a new bioconverted Korean red ginseng extract. This product uses advanced processing to enhance the bioavailability of key active compounds.
Why it matters
Conventional ginseng relies on an individual's gut microbiome for effective conversion and absorption, which can vary significantly between people. This new extract performs that bioconversion before consumption to ensure more consistent nutrient delivery.
The product utilizes enzymatic bioconversion to generate F2 and Compound K ginsenosides while incorporating gamma-cyclodextrin microencapsulation. This formulation process ensures a 3-year shelf life for the ingredient.
The players
US Food and Drug Administration
The US Food and Drug Administration is the federal agency responsible for regulating food safety and dietary supplement ingredient notifications in the United States.
The details
The technology aims to overcome the natural bitterness of ginseng through encapsulation while increasing the concentration of minor ginsenosides. By standardizing the conversion process, the extract avoids the variability typically associated with biological digestive absorption.
Timeline
The product has an established 3-year shelf life.
The Big Picture
This notification follows the regulatory framework established by the Dietary Supplement Health and Education Act of 1994 to evaluate new dietary ingredient safety. It marks a continued effort by federal regulators to oversee the evolving market of concentrated botanical extracts.
Consumers may find more consistent potency in future ginseng-based supplements due to the pre-processed nature of the bioconverted extract. The encapsulation technology also reduces the typical bitter aftertaste, potentially improving the supplement experience for daily users.
The takeaway
Advancements in enzymatic bioconversion are helping supplement manufacturers bypass the limitations of human gut microbiome variability. Users interested in herbal extracts should look for products that utilize standardized conversion methods to ensure they are getting the intended levels of active ginsenosides.
Further reading
For more on evolving dietary ingredient standards, visit the United States Nutrition section.
Source note: This article includes information reported by Supplysidesj.
Live Poll
Do you trust that bio-engineered supplement processing significantly improves the health benefits you receive?
